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avid N. Campbell (Denver, Colo). Obviously you and your
oauthors have put a lot of work and effort into this very impres-
ive study, which does cover a large number of pediatric and
oung adults. We actually use 18 and under for pediatric age, so
here are some young adults in this “pediatric” group, but 3500
atients is an impressive number of patients over a decade between
995 and 2005. These were all transplanted and then entered into
he UNOS database. Again, this consists of a great deal of time and
ffort to get this information. I have two comments and then two
uestions.
As you pointed out well in the manuscript, in pediatric heart
ransplant recipients, PVR is not an identifier for poor outcome and
oor survival as it is in adults. This is something that gets lost
ometimes in the pediatric patient group.
You have re-emphasized that the predictors of pretransplant
linical status remain a significant predictor of poor outcomes and,
s you have pointed out, these are hospitalization, intensive care
nit care, mechanical ventilation, and particularly ECMO support.
ll of these portend a very poor outcome. h
54 The Journal of Thoracic and Cardiovascular Surgery ● JanuI think the message to be taken from this is that earlier inter-
ention in the pediatric group is warranted, and we are far behind
he adults in terms of using ventricular assist devices. I know
olumbia, particularly, is a large user of those, and I know that you
ave already set out a scale very much like you have used for this
ediatric group. I think it is very important that the pediatric heart
ransplant surgeons begin to use mechanical assist devices much
arlier. We are obviously coming onto that scene later than we
hould be. Part is because we do not have good ventricular assist
evices in children, but they are being developed and ideally by
009, with the money that is being put into five programs, we will
ave some information and better devices.
My first question to you is, have you actually used this scoring
ystem in any patients to predict outcome, or is this just a scale that
ou have somewhat arbitrarily determined and are planning on
sing?
Dr Davies. We have not used it yet. We have developed the
core recently and are in the early stages of planning to use it.
mportantly, the score needs to be validated before we can use it
xtensively. This presents a challenge because the UNOS data
nclude all patients who have undergone transplantation in the
nited States, so it is harder to find patients who are not contained
n the database. Our current thinking is to use some Canadian data
o validate it, as one of our coauthors is at the University of
oronto. Before that, our intention is to use it as a guide, especially
o attempt to reduce the particularly high risk associated with
actors like ECMO. The score reinforces the need to wean children
rom ECMO before transplantation if at all possible. Therefore, at
his time, the score is important both to help with prognostication
nd discussions with families and then to guide clinical therapy in
erms of getting people toward a better score before transplanta-
ion.
Dr Campbell. My second question concerns a circumstance
esembling one of the two examples that you described. We
ecently performed transplantation in a young child with exactly
he circumstances you pointed out. The child had an operation that
id not go well, ended up on ECMO for a long period of time, and
nded up undergoing transplantation, which in your group would
ortend again a poor outcome. That child actually did quite well,
o it is going to be difficult, I think, to predetermine exactly how
hese children will do. In our own institution, we were questioned
s to whether we should even have undertaken that transplant. My
uestion to you is, what would you do with patients like that in the
uture who are on say beyond that 10 scoring in your category and
re very high risk? Would you just not transplant them? Obviously,
art of the idea would be to put them on a ventricular assist device,
ut even somebody that has been on ECMO for a period of time is
ot really a good device candidate, as you pointed out. Again, the
olumbia group has a scale that they use to determine whether to
lace devices, and I am not sure some of these patients would even
eet the criteria for that. So where do you go with those patients?
o you decide you will not attempt transplantation, or do you go
head and try?
Dr Davies. Given the lack of validation, it is difficult to say not
o transplant them. In addition, although a 50% 1-year mortality is
bviously high, the mortality for the same patient without a trans-
lant is higher. More research needs to clarify which patients will
ave the most improvement with transplantation and what the best
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Davies et al Cardiothoracic Transplantationethod is for optimizing the limited supply of donor organs before
e would suggest that this score should be used to exclude people
rom transplantation.
Dr John Hawkins (Salt Lake City, Utah). I just have a couple
f quick questions. How did you pick these risk criteria? How did
ou pick just seven? Maybe I do not understand the methodology,
ut why did you not include CHD or multiple previous operations
r ECMO as a risk factor in doing the modeling?
Second, have you used this clinically to turn someone down
et? In someone who has three or four or five risk factors, have you
ctually used this information in your practice?
Dr Davies. To answer your second question first, we have not
tarted using the score yet and the score needs to be validated
efore its use. We need to refine the accuracy of these data before
e can turn people down for transplantation.
With regard to our choice of risk factors, we went through
nternal Columbia criteria for separating patients who were at
tandard risk versus high risk for transplant. Most of these criteria
ere based on consensus statements or older data. In addition, we
ent through the literature and tried to identify other factors that
ight be predictive as well.
Specifically, in terms of not including CHD, our own data
uggest that patients with CHD as a whole group have similar
utcomes and that it is the patients with complex CHD who
ccount for increased risk. Unfortunately, the UNOS data set does
ot allow one to separate those patients. Therefore, as an a priori
ecision, we did not want to include it in our list of criteria. g
The Journal of Thoracicowever, it did turn out to be a reliable risk factor even in the
NOS data set, so it was included in our risk score based on
redetermined methodology. Other information provides signifi-
ant opportunity for improvement: either single institution studies
r the Pediatric Heart Transplant Study Group, which includes
uch more detailed diagnosis information that will allow us to
ease out the true contribution of CHD to posttransplant outcomes.
Dr Jonathan Chen (New York, NY). I just want to make a
omment. One big impetus for us to pursue this question at all is
hat we lag behind the adult service mainly because the numbers
re so small. We have had a lot of success in the adult arena with
n alternate list comprised of a separate group of patients with
hom we have a very stern conversation pretransplant indicating
hat they are not candidates in the routine pool but could be
andidates on the alternate list made for patients who are really
igh risk. I believe it does make clear for families and for the
atients themselves the gravity of the situation. What we did find
ust anecdotally in the adult world with the alternate list (these are
rgans that are passed over by every other program) is that about
0% of them end up being normal hearts. They just do not have the
ppropriate size to recipient available. This is particularly pertinent
or the pediatric group. As I am sure everyone knows, you will
ften get a telephone call about a young infant donor and every-
ody has passed it over because it is simply not the right size. It is
ot that these patients get “marginal hearts” and thereby stack
onor variables with recipient variables. I think it gives them a
ood shot at transplant, albeit at high risk.
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